Upon the decision of Ankara 10th Administration Court, the Competition Board reevaluated the allegation that Allergan İlaçları Tic. A.Ş. abused its dominant position by not supplying the “Botox” branded drug to the National Pharmaceuticals Medical Devices Warehouse. 
Previously, the decision no 13-01/3-3 that it was not necessary to initiate an investigation regarding the allegations that were the subject of the file pursuant to the Article 41 of the Act no 4054 was taken on 03.01.2013 as a result of the preliminary inquiry conducted upon the complaint in question. Later, the aforementioned Board decision was annulled by the decision of Ankara 10th Administrative Court dated 22.09.2021 and no 2021/961 E., 2021/1452 K. 
The Board discussed the information and documents in the file at its meeting dated 28.10.2021 and took the decision no 21-53/732-M that an investigation concerning Allergan İlaçları Tic. A.Ş. would be initiated in order to ensure that the aforementioned Court decision is fulfilled.

* Investigation decisions taken by the Competition Board are announced to the public following the notification of the decision to the undertakings or associations of undertakings about which an investigation has been initiated. Those announcements are made within the framework of informing the public about the decisions of the Competition Board and cannot be interpreted to mean that the undertakings or associations of undertakings about which an investigation has been initiated have violated the Act no 4054, or they are or will be subject to penal sanctions under the Act.